Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IMAB362 monotherapy in advanced gastric and lower esophageal adenocarcinoma
2009-017365-36Phase 2Completed
- Sponsor
- Ganymed Pharmaceuticals
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zolbetuximab in gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Ganymed Pharmaceuticals. Primary endpoint: Rate of remission (CR, PR) per RECIST. Started Feb 2010; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2009-017365-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017365-36.